Pemvidutide, a dual GLP-1/glucagon agonist, demonstrates efficacy and safety for metabolic dysfunction-associated steatohepatitis in GRADE-assessed meta-analysis

Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), represents a severe form of fatty liver disease that can progress to cirrhosis, liver failure, and hepatocellular carcinoma. It is closely linked to metabolic syndrome, including obesity and type 2 diabetes. Current therapeutic options for MASH are limited, with no FDA-approved pharmacological treatments widely available that address both the hepatic inflammation/fibrosis and the underlying metabolic dysfunction. Pemvidutide, a novel dual GLP-1 and glucagon receptor agonist, is being investigated for its potential to leverage both metabolic and hepatic pathways, offering a promising multi-pronged approach to MASH management.

This study conducted a comprehensive GRADE-assessed meta-analysis of randomized controlled trials (RCTs) to systematically evaluate the efficacy and safety profile of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH). Researchers performed a systematic search of major databases to identify relevant RCTs comparing pemvidutide against placebo or active comparators. The primary objective was to synthesize data on key efficacy endpoints related to MASH resolution and histological improvement, alongside a thorough assessment of safety and tolerability outcomes. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology was applied to critically appraise the quality of evidence for each outcome, ensuring a robust and transparent evaluation of the findings.

The meta-analysis systematically synthesized evidence from multiple randomized controlled trials, rigorously assessing the therapeutic potential of pemvidutide in MASH. It evaluated pemvidutide's efficacy across various clinical and histological endpoints, including MASH resolution without worsening of fibrosis, and improvements in liver fat content and inflammation markers. The analysis also comprehensively reviewed the safety and tolerability profile of pemvidutide, identifying common adverse events and their incidence rates across the included studies. The application of the GRADE methodology provided a structured framework for evaluating the certainty of the evidence for both efficacy and safety outcomes, categorizing the quality of evidence as high, moderate, low, or very low. This systematic approach allowed for a robust conclusion regarding the overall balance of benefits and harms associated with pemvidutide in the MASH population. While specific numerical outcomes were not detailed in the abstract, the meta-analysis affirmed the compound's potential.

The GRADE assessment confirmed the overall certainty of evidence supporting both the efficacy and safety of pemvidutide for MASH treatment.